Longitudinal Natural History Study of Retinal Function in Eyes of Patients With Diabetes
Start Date
6/1/2026
Completion Date
12/1/2032
Summary
A considerable hurdle to the development of novel, more effective therapies for diabetic retinal disease is the limited number of primary endpoints available for use in regulatory trials. Current endpoints necessitate long trial durations and a greater number of participants to show efficacy. Thus, a better understanding of the structural and functional changes in the retina occurring in people with diabetes is essential for developing primary endpoints and validating surrogate and clinical endpoints.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Visual Acuity
Reading Speed
Visual Field testing
Contrast sensitivity
Electroretinography (ERG) and pupillography in light- and dark-adapted states
Ultrawide field-color photograph
Ultrawide field-Fluorescein angiogram
Optical coherence tomography
Optical coherence tomography- Angiography
Conditions
Locations
Southeast Retina Center, P.C.
Augusta, Georgia 30909
United States
Boston Medical Center Corporation
Boston, Massachusetts 02118
United States
Henry Ford Health System
Detroit, Michigan 48202
United States
Mayo Clinic
Rochester, Minnesota 55905
United States
Retina-Vitreous Consultants, Inc.
Monroeville, Pennsylvania 15146
United States
Pittsburgh Clinical Trial Consortium
Sewickley, Pennsylvania 15143
United States